ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.

Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, Suriano S, Swiderska-Syn M, Sion A, Harris J, Edwards AR, Rytlewski JA, Sanders CM, Yusko EC, Robinson MD, Krieg C, Redmond WL, Egan JO, Rhode PR, Jeng EK, Rock AD, Wong HC, Rubinstein MP

Open source

DOI: 10.1016/s1470-2045(18)30148-7
Published: 2018 May
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-18-30148-7,
  title = {ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.},
  author = {Wrangle JM and Velcheti V and Patel MR and Garrett-Mayer E and Hill EG and Ravenel JG and Miller JS and Farhad M and Anderton K and Lindsey K and Taffaro-Neskey M and Sherman C and Suriano S and Swiderska-Syn M and Sion A and Harris J and Edwards AR and Rytlewski JA and Sanders CM and Yusko EC and Robinson MD and Krieg C and Redmond WL and Egan JO and Rhode PR and Jeng EK and Rock AD and Wong HC and Rubinstein MP},
  year = {2018},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(18)30148-7},
  url = {https://doi.org/10.1016/s1470-2045(18)30148-7}
}

RIS

TY  - JOUR
TI  - ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
AU  - Wrangle JM
AU  - Velcheti V
AU  - Patel MR
AU  - Garrett-Mayer E
AU  - Hill EG
AU  - Ravenel JG
AU  - Miller JS
AU  - Farhad M
AU  - Anderton K
AU  - Lindsey K
AU  - Taffaro-Neskey M
AU  - Sherman C
AU  - Suriano S
AU  - Swiderska-Syn M
AU  - Sion A
AU  - Harris J
AU  - Edwards AR
AU  - Rytlewski JA
AU  - Sanders CM
AU  - Yusko EC
AU  - Robinson MD
AU  - Krieg C
AU  - Redmond WL
AU  - Egan JO
AU  - Rhode PR
AU  - Jeng EK
AU  - Rock AD
AU  - Wong HC
AU  - Rubinstein MP
PY  - 2018
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(18)30148-7
UR  - https://doi.org/10.1016/s1470-2045(18)30148-7
ER  -

APA

JM, W., V, V., MR, P., E, G., EG, H., JG, R., JS, M., M, F., K, A., K, L., M, T., C, S., S, S., M, S., A, S., J, H., AR, E., JA, R., CM, S., EC, Y., MD, R., C, K., WL, R., JO, E., PR, R., EK, J., AD, R., HC, W., & MP, R. (2018). ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(18)30148-7

Source records

pubmed · retrieved 2026-09-27T15:59:47.282Z